Kornimate/medical-research-clean huggingface dataset:
the acute effects of oleic acid enriched-diets on lipids, insulin sensitivity and serum inflammatory markers

Conditions: Lipid Profile

Summary: objectives: to investigate the acute effects of olive oil, palm olein and lard on lipid profile, insulin sensitivity and inflammatory markers. hypothesis: different dietary fats will alter lipid profile, insulin sensitivity and inflammatory markers postprandially.

a randomized, single blind, crossover design was undertaken to test meals enriched with palm olein vs olive oil vs lard. volunteers were asked to participate in three postprandial challenges, separated by at least 3-days. subjects were provided a low fat meal(\<10g fat) the day before the intervention. fasting blood was collected the next day and the subjects were instructed to consume test meals (50g high fat meal). further venous blood was collected at 30 min, 1h, 2h, 3h and 4h postprandially. primary outcome variable: triacylglycerol (tag) secondary outcome variables: insulin sensitivity (glucose, insulin), non esterified fatty acids (nefa), inflammatory markers

Eligibility criteria:
inclusion criteria: * age: 18-45 years * bmi : 18.5-30 kg/m\^2 * healthy, men exclusion criteria: * medical history of cardiovascular disease, cancer, diabetes or chronic diseases * bmi \ 30 kg/m\^2 * waist hip ratio \> 0.9 * total cholesterol \> 5.2 mmol/l * triacylglycerol (tag) \> 2.2 mmol/l * current use of antihypertensive or lipid lowering medication

Keywords: fat inflammation lipids total cholesterol triglycerides insulin sensitivity
resectoscopic treatment of atypical endometrial polyps in fertile women

Conditions: Atypical Endometrial Polyps; Atypical Endometrial Hyperplasia

Summary: the study aims to evaluate the long-term efficacy and prognosis of hysteroscopic resection and coagulation of the base of endometrial polyps with focal atypia in fertile women.

the introduction of hysteroscopy in clinical practice changed significantly our knowledge of uterine cavity, but did not stimulate the start of big studies with aim to evaluate the feasibility of conservative treatments for better defined diseases as endometrial polyp. the use of curettage(d\&c) has led the gynecologists to consider diffuse atypical endometrial hyperplasia and atypical polyp as the same disease. the treatment of these precancerous lesions recommended by scientific societies is aggressive (hysterectomy). surprisingly, regarding hysterectomy we did not observe management modifications after the introduction of endoscopic techniques, as happened in other surgical disciplines. to evaluate costs and health benefits of operational hysteroscopy we started in our institute a study protocol in 1998. in a first trial we studied a conservative treatment of postmenopausal woman with high anesthesiologic risk who had endometrial polyps with atypia and no involvement of the base (scrimin f. am j obstet gynecol 2006;195:1328-30). the good initial results and the request of conservative treatments by some women, desiring pregnancies, encouraged us to start this preliminary trial to evaluate the long-term efficacy and prognosis of hysteroscopic resection and coagulation of the base of endometrial polyps with focal atypia in a little sample of fertile women. other studies suggest progestin treatment of well differentiated carcinoma in young women who desired to preserve their fertility. there is no evidence of a correlation between the tendency to develop endometrial polyps and the risk of endometrial carcinoma. the risk of malignant degeneration of endometrial polyps is not well known, but seems to range between 0.5% and 6%. on this background, we decided to study in the same population of fertile women and with a quasi-randomised design the possible additional effect of levonorgestrel-releasing intrauterine device (lng-iud). comparison: women assigned to odd numbers underwent polyp resection and endometrial surveillance with insertion of levonorgestrel intrauterine system (iud group), women assigned to even numbers underwent polyp resection and endometrial surveillance without insertion of levonorgestrel intrauterine system (no iud or control group).

Eligibility criteria:
inclusion criteria: * women in fertile age desiring to preserve their uterus * atypical polyps, without atypia in the base. the hysteroscopic and histologic criteria for inclusion in the study were: proliferative, secretive, dysfunctional endometrium or simple hyperplasia in 4 random biopsies. exclusion criteria: * women with adenomatous or atypical hyperplasia in the random biopsies

Keywords: atypical endometrial polyps atypical endometrial hyperplasia hysteroscopic resection conservative treatment fertile women
the beat pain better trial

Conditions: Osteoarthritis; Chronic Pain Management

Summary: the beat pain better study examines strategies to increase the reach of evidence-based interventions for persons with osteoarthritis (oa) in communities that experience disparities. the study is a hybrid type 3 effectiveness-imple-mentation trial using sequential, multiple assignment, ran¬domi¬zation to evaluate 1) two text mes¬saging strat¬egies to reach persons with oa and enroll them in physical activity counseling provided by physical therapists; and 2) two strat¬egies to engage enrolled persons in the walk with ease (wwe) intervention for sustained self-management.

we will conduct a hybrid type 3 effectiveness-imple¬mentation trial with a sequential, multiple assignment, ran¬domi¬zed design. primary outcome is physical activity (pa) counseling reach (aim 1). secondary outcomes evaluate reach of wwe (aim 2) and outcomes across re-aim domains (aim 3). persons with icd-10 diagnosis codes indicating oa will be identified from ehrs in partnering clinics and sent text message (tm) invitations to participate in pa counseling. phase i randomization will test two tm strategies: weekly tms over 4 weeks with or without motiva¬tional messages. phase ii randomization for those who enroll in pa counseling and provide consent will test two formats for the wwe aaebi; self-directed or enhanced self-directed delivery. participants will be randomized with 1:1 distribution at each randomization. participants may consent and enroll for randomization to a wwe format even if they did not receive the tm intervention. the first randomization is performed using the tm platform (azara or similar), stratified by site. the second randomization is performed using the redcap randomization module, also stratified by site and by baseline pa level. randomization schemas will be developed before enrollment. randomization errors will be recorded as protocol deviations.

Eligibility criteria:
inclusion criteria: 1. age 45 or older; 2. visit in participating medical clinic within the past 6 months 3. oa diagnosis code related to lower extremity and/or spine on the problem list or associ¬ated with an encounter in the past 6 months 4. has functioning cell phone able to receive calls and texts exclusion criteria: 1. unable to participate in a regular walking program defined as the ability to walk for at least five minutes with or without the use of an assistive device. 2. medical contraindication to participation in physical activity 3. unable to communicate in either spanish or english

Keywords: osteoarthritis chronic pain physical therapy self-management
effect of colostrum on gut permeability and endotoxin level in chronic alcoholic disease

Conditions: Leaky Gut Syndrome

Summary: chronic alcohol ingestion is related with leaky gut syndrome. colostrum is well-studied that it has a effect of decreasing the degree of leaky gut syndrome. so the investigators are planning to find out whether colostrum has a effect of decreasing the degree of leaky gut syndrome.

we randomly sort the participant as placebo group and colostrum group. each group consists of 17 people. and the duration of our study for one participant is 3 weeks. (participant takes colostrum for 3 weeks.) when a person gets leaky gut syndrome, his or her endotoxin and lactulose/mannitol ratio (l/m ratio, in urine) can elevate. so we will compare the value of those two parameters and lft. etc. after the administration of colostrum or placebo.

Eligibility criteria:
inclusion criteria: * men aged over 20 who's alcohol consumption per day is 20.0gram average * he must agree to participate this trial voluntarily. * liver function test within 3 months : ast more than 30 or alt more than 33 or gamma-gt more than 46 * men who have result of ultra-sono result of abdomen without liver cirrhosis exclusion criteria: * hepatitis b or c , liver cirrhosis patient * men who have undergo bowel operation * men who are taking nsaids * periodontitis or gerd or other g-i tract infection within 2 weeks before enrollment * men who have been given anticancer drug within one year * men who have been given antibiotics within 2 weeks * creatinine level \>= 1.4mg/dl * men who are taking g-i motility drugs or anti-ulcer drug * milk allergy
utility of xcl1 as a prognostic marker in acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia

Summary: the purpose of the study is to determine the utility of xcl1 in the prognosis of acute lymphoblastic leukemia.

each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. xcl1 is a lymphotactin that belongs to a cytokine subfamily called c or γ with only one cysteine in the n-terminal residue. it has been found with significant expression of receptor mrna xcl1 (xcr1) in t and b lymphocytes and related to hematological neoplasms. for these reasons, xcl1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Eligibility criteria:
inclusion criteria: patients with newly diagnosed acute lymphoblastic leukemia . exclusion criteria: * patients with prior treatment with chemotherapeutic agents. * patients treated with immunosuppressants. * patients under 12 months old. * patients with a diagnosis or history of autoimmune diseases. * patients with a diagnosis or history of immunosuppressive diseases. * patients who do not agree to sign a letter of informed consent.

Keywords: all xcl1 cytokines prognosis
comparison of cryoablation of pericapsular nerve group (peng) to fascia iliaca catheter in patients with a hip fracture

Conditions: Hip Fractures

Summary: the purpose of this study is to determine if patients with hip fractures who undergo cryoablation of the peng have improved pain control 30 days from surgery when compared to those who have a fascia iliaca catheter.


Eligibility criteria:
inclusion criteria: * patients undergoing hip fracture repair aged 18-85. exclusion criteria: * patients who have an exclusion to regional anesthesia. * patients who are pregnant assessed via self-report or pregnancy test if they have taken one. * non-english speakers * patients who already had their fracture repaired"

Keywords: hip fractures
a randomized, double-blind, placebo-controlled trial of flumazenil for the treatment of obsessive compulsive disorder

Conditions: Obsessive Compulsive Disorder

Summary: the purpose of this study is to evaluate the efficacy of flumazenil in the outpatient treatment of obsessive compulsive disorder (ocd).


Eligibility criteria:
inclusion criteria: * able to understand and provide written informed consent. * age 19-60, inclusive. * diagnosis documented according to dsm-iv of ocd. * exhibits moderate to severe ocd symptoms and a minimum score of 16 or greater -ybocs at screening. * willing and able to discontinue current medications taken for the treatment of ocd. * able to attend and participate in all study visits. * agree to continue if in current psychosocial therapy throughout the remainder of the study. * if female and of child-bearing potential, willing to use an acceptable method of birth control for the duration of the study. * if male, willing to use barrier method of birth control or had previous vasectomy. exclusion criteria: * have other dsm-iv axis i diagnoses. * pregnant as confirmed by urine analysis, or lactating, or unwilling to comply with use of contraception. * unwilling or unable to washout (discontinue) from prohibited medications such as antidepressants (see appendix 2). * depression symptoms with a score of 15 or greater on the madrs at screening. * current suicidal ideation or plan within the last 30 days. * have a medical condition which, in the opinion of the investigator, makes study participation unsafe or noncompliant. * abnormal physical exam or laboratory values which, in the opinion of the investigator, makes study participation unsafe or may require introduction of concomitant medications during the course of the study. * benzodiazepine and/or similar sedative-hypnotic or anxiolytic use or abuse within 15 days of potential flumazenil treatment: patients must not be habituated to benzodiazepines and must provide a urine sample that is negative for benzodiazepines, must not be taking supra-therapeutic doses of zolpidem (ambientm) or zaleplon (sonatatm ). (see appendix 2). * patients who are taking phenobarbital for a documented seizure disorder can be admitted. patients with a seizure disorder being managed with clonazepam (klonopintm ) or other benzodiazepine cannot participate, patients must not be taking tca, lithium, methylxanthines, isoniazid, propoxyphene, monoamine oxidase inhibitors, bupropion hcl, and cyclosporine. (see appendix 2). * previously treated with flumazenil for ocd. * aids as determined by self-report.

Keywords: ocd
decision impact trial of the exodx prostate (intelliscore)

Conditions: Cancer of the Prostate

Summary: the purpose of this research study is to investigate the utility of a validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy.

primary objective(s) 1. evaluate performance of the exodx prostate(intelliscore) (epi) to reduce the number of initial prostate biopsies by greater than or equal to 15% for men with an elevated prostate-specific antigen 2-10ng/ml presenting for a biopsy in consultation with their urologist. 2. compare performance of both the exodx prostate(intelliscore) 15.6 and 20 cut-points with respect to the biopsy decision process. 3. assess physician satisfaction with the exodx prostate(intelliscore) report including test result presentation, graphics and interpretation. 4. assess urologist / patient satisfaction for ease of understanding test results and role on biopsy decision process. secondary objectives 1. determine the medical economic impact of the exodx prostate(intelliscore) test in the prostate biopsy decision process. 2. correlation of the exodx prostate(intelliscore) score with the actual biopsy result by utilizing the receiver operating characteristic of the area under curve for discriminating high-grade (greater than or equal to gleason score 7, international society of urological pathology 2 and 3) from low-grade (gleason score 6, international society of urological pathology 1) and benign disease on initial prostate needle biopsy.

Eligibility criteria:
inclusion criteria: * 50 years of age * clinical suspicion for prostate cancer * elevated prostate-specific antigen between: 2.0 - 10 ng/ ml * no clinical history of a prior negative biopsy exclusion criteria: * history of prior prostate biopsy. * use of medications or hormones that are known to affect serum prostate-specific antigen levels within 3-6 months of study enrollment. * clinical symptoms of urinary tract infection (including prostatitis) at the time of enrollment. * history of prostate cancer. * history of invasive treatments for benign prostatic hypertrophy (benign prostatic hyperplasia) or lower urinary track symptoms within 6 months of study enrollment. * known hepatitis (all types) and/or hiv documented in patient's medical record. * patients with history of concurrent renal/bladder tumors.
management of displaced supracondylar fractures of the humerus using lateral vs. crossed k-wires

Conditions: Humeral Fractures

Summary: completely displaced (type iii) supracondylar fractures of the humerus are treated in the operating room and are held together with pins stuck into the bone. there are two ways of inserting the pins: crossed and laterally. the crossed method is often used because it is thought to be more stable, but this method also carries a risk of hitting the ulnar nerve. it is not known which method is more stable. our hypothesis is that loss of reduction will be equivalent between the two pinning methods.

children with type iii supracondylar fractures of humerus who meet the study inclusion criteria will be invited to participate in the study by the on call orthopaedic surgeon. all patients will be required to provide informed consent. patients will then be randomized through a random number software package and will commence immediately after confirmation of inclusion into the study. the fracture is reduced and fixed percutaneously either with crossed or lateral k wires, according to which group the subject was randomized to. post reduction antero-posterior and lateral radiographs of the elbow are done in the operating room. above elbow cast is applied. radiographs are taken at follow-up visits to the clinic. the radiographs are measured to determine loss of reduction between immediate post-op films and films taken immediately prior to pin removal.

Eligibility criteria:
inclusion criteria: * male and female patients scheduled for closed reduction and k wiring of supracondylar fractures of the humerus under general anaesthesia a * type-3 supracondylar fractures of the humerus. * aged 3 to 7 years old * consent to participate in the study exclusion criteria: * open supracondylar fractures of the humerus * children with pre-operative ulnar nerve injury * supracondylar fractures with compartment syndrome needing fasciotomy * supracondylar fractures needing vascular repair * refusal to provide informed consent

Keywords: supracondylar fracture humerus ulnar nerve injury baumann's angle supracondylar fracture of the humerus
the role of tvsg and hs in determining endometrial pathologies

Conditions: Abnormal Uterine Bleeding

Summary: although hysteroscopy (hs) and transvaginal ultrasonography (tvsg) are methods in the diagnosis of aub, there is some suspicion about their efficacy. the aim of this study was to determine the efficacy and safety of hs and tvsg on diagnosing abnormal uterine bleeding(aub) .216 women admitted to the investigators clinic (sisli ethal training and research hospital, obstetrics and gynecology department obstetrics service ) between 21-51 years of age. these patients were divided into two groups; menopause (71women) and pre-menopause (145 women). hs and endometrial sampling were performed both groups after tvsg.the success of these methods was assessed by kappa analysis


Eligibility criteria:
inclusion criteria: * patients who have no history of hysteroscopy and curettage, * patients who have no history of ovulatory dysfunction * women who have active vaginal bleeding. exclusion criteria: * presence of genital infections/pid * presence of pregnancy * presence of vaginal or cervical pathology causing vaginal bleeding * women who are receiving hormonal treatment (coc/hrt) * patients formerly diagnosed with endometrial pathology * patients having coagulopathy * women who are using intrauterine device.

Keywords: transvaginal ultrasonography hysteroscopy abnormal uterine bleeding
evaluation of p-321 ophthalmic solution compared to placebo in subjects with dry eye disease

Conditions: Dry Eye Disease

Summary: the purpose of this study is to evaluate the effect of treatment with 0.017% p-321 on dry eye symptoms.

this is a multi-center, randomized, double-masked, placebo-controlled, parallel group phase 2b trial designed to evaluate symptoms and signs in subjects with mild to moderate dry eye disease. eligible patients, will be treated with placebo during 2-week placebo run-in period. subjects will then be randomly assigned in a double-masked, 1:1 ratio to either 0.017% p-321 ophthalmic solution or placebo tid for 28 days. this study is designed to evaluate the changes in symptoms. safety will be assessed throughout the study by adverse events.

Eligibility criteria:
inclusion criteria: 1. provide written informed consent 2. male or female subjects aged 18 to 80 years, inclusive 3. have a history of dry eye disease (ded) in both eyes 4. be on stable regimens of other needed medications 5. have a bcva of +0.7 or better as assessed by early treatment of diabetic retinopathy study (etdrs) 6. have reported symptoms 7. have the following signs in at least one eye: schirmer score without anesthesia of \>1 and \<10 mm at 5 minutes and staining of conjunctival and corneal areas of the eye. 8. have normal lid anatomy exclusion criteria: 1. have undergone refractive eye surgery in the past 12 months 2. have undergone previous eyelid surgery in either eye (external blepharoplasty not resulting in exposure or abnormal blinking is allowed) 3. have lid irregularities or deformities 4. have a history of glaucoma, a history of an elevated lop within the past year, or an lop in either eye \> 25 mmhg at the screening visit (visit 1) 5. have any clinically significant, uncontrolled, or unstable medical or surgical conditions that could affect his or her ability to participate 6. have permanent punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction. removable punctal plugs are allowed if they have been used regularly for at least 60 days prior to the screening visit. however, if a plug comes out during the study it must be promptly replaced. 7. have clinical findings of severe meibomian gland dysfunction (mgd) in the study eye 8. are pregnant or breast feeding 9. use of any investigational product or device within 28 days prior to the screening visit or during the study
influence of shenqu xiaoshi oral liquid on intestinal microbiome of children with functional dyspepsia

Conditions: Dyspepsia; Child

Summary: it has been confirmed that treatment with shenqu xiaoshi oral liquid (sxol) effectively improves dyspeptic symptoms and is well tolerated. it is not inferior to domperidone syrup and leads to sustained improvement in chinese children with functional dyspepsia (fd). this study aims to evaluate the possible regulatory effect of sxol on intestinal microbiome in children with fd, further exploring its related mechanism.


Eligibility criteria:
inclusion criteria: 1. outpatients aged 3-14 years old; 2. meeting ≥1 condition(s): (1)postprandial fullness;(2)early satiation;(3)epigastric pain or burning not associated with defecation; 3. having symptoms at least 2 months and at least 4 days per month before diagnosis; 4. during the 2-wk lead-in period, no relevant drugs for the treatment of dyspepsia and anorexia were used, good eating habits have been established, and the fd symptoms still existed (symptom score≥3). 5. informed consent was obtained from the parents/guardians of the participant. if the child was more than 8 years old, additional informed consent would be required from the participant. exclusion criteria: 1. anorexia and dyspepsia caused by certain drugs and confirmed organic diseases such as erosive gastritis, peptic ulcer, etc; 2. severe malnutrition; 3. serious primary diseases of the cardiovascular, nervous, respiratory, hepatobiliary and endocrine systems; 4. mental disorders, intellectual disabilities, and/or communication impairments; 5. lactose intolerant or allergic to the ingredients of shenqu xiaoshi oral liquid or traditional chinese medicine; 6. probiotics or antibiotics within 4-wk; 7. participated in a clinical trial within the past 12-wk; 8. individuals deemed unsuitable for this clinical trial.